IP Library Granted Patent US 8,822,417
Granted Patent B2
US 8,822,417 · App. 13/463,944 · Granted Sep 2, 2014

Albumin variants

Inventors: Jan Terje Andersen (Oslo, NO); Bjorn Dalhus (Hagen, NO); Inger Sandlie (Oslo, NO); Jason Cameron (Nottingham, GB); Andrew Plumridge (Derbyshire, GB); Esben Peter Friis (Herlev, DK); Karen Delahay (Nottingham, GB)
Assignee: Novozymes Biopharma DIC A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,822,417
App. No.
13/463,944
Granted
Sep 2, 2014
Kind
B2
Abstract

Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.

Claims (20)

1. A polypeptide which is a variant of albumin, comprising one or more alterations at one or more positions corresponding to 104, 106, 108, 109, 110, and 120 in SEQ ID NO: 2 with one or more of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y.

2. The polypeptide according to claim 1 wherein the one or more alterations are substitution(s).

3. The polypeptide according to claim 1 , comprising a conjugatable thiol group on the polypeptide.

4. A fragment of the polypeptide according to claim 1 , wherein the polypeptide is a fragment with at least 500 amino acids.

5. A fusion polypeptide, conjugate, associate, nanoparticle, microparticle or composition comprising the polypeptide of claim 1 .

6. The polypeptide according to claim 1 , wherein the sequence identity of the polypeptide to SEQ ID NO: 2 is more than 97%.

7. The polypeptide according to claim 1 , wherein the sequence identity of the polypeptide to SEQ ID NO: 2 is more than 99%.

8. The polypeptide of claim 1 , wherein one alteration corresponds to position 104 in SEQ ID NO: 2 with one of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y.

9. The polypeptide of claim 1 , wherein one alteration corresponds to position 106 in SEQ ID NO: 2 with one of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y.

10. The polypeptide of claim 1 , wherein one alteration corresponds to position 108 in SEQ ID NO: 2 with one of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y.

11. The polypeptide of claim 1 , wherein one alteration corresponds to position 109 in SEQ ID NO: 2 with one of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y.

12. The polypeptide of claim 1 , wherein one alteration corresponds to position 110 in SEQ ID NO: 2 with one of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y.

13. The polypeptide of claim 1 , wherein one alteration corresponds to position 120 in SEQ ID NO: 2 with one of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y.

14. A method of making a polypeptide according to claim 1 comprising:

(a) providing a nucleic acid encoding a parent albumin comprising the sequence of SEQ ID NO: 2;

(b) modifying the sequence of step (a), to encode a polypeptide which is a variant albumin having one or more substitutions at one or more position corresponding to positions in SEQ ID NO: 2 selected from the group consisting of: 104, 106, 108, 109, 110, and 120.

15. The method of claim 14 further comprising:

(c) introducing the modified sequence of step (b) in a suitable host cell;

(d) growing the cells in a suitable growth medium under condition leading to expression of the polypeptide; and

(e) recovering the polypeptide from the growth medium.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 68165 FRAME: 276. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 9, 2024
From: ALBUMEDIX LTD
To: SARTORIUS ALBUMEDIX LIMITED
Reel/Frame 068526/0034 →
CHANGE OF NAME Recorded Aug 2, 2024
From: ALBUMEDIX LTD
To: SARTORIUS ALBUMEDIX LIMITED
Reel/Frame 068165/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2018
From: NOVOZYMES BIOPHARMA DK A/S (BI-NAME ALBUMEDIX A/S)
To: ALBUMEDIX LTD
Reel/Frame 046093/0808 →
CHANGE OF NAME Recorded Jul 15, 2016
From: NOVOZYMES BIOPHARMA DK A/S
To: ALBUMEDIX A/S
Reel/Frame 039360/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2014
From: UNIVERSITY OF OSLO; NOVOZYMES A/S; NOVOZYMES BIOPHARMA UK LIMITED
To: NOVOZYMES BIOPHARMA DK A/S
Reel/Frame 033196/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2012
From: FRIIS, ESBEN PETER
To: NOVOZYMES A/S
Reel/Frame 028893/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2012
From: CAMERON, JASON; PLUMRIDGE, ANDREW; DELAHAY, KAREN
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 028893/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2012
From: ANDERSEN, JAN TERJE; DALHUS, BJORN; SANDLIE, INGER
To: UNIVERSITY OF OSLO
Reel/Frame 028893/0417 →
Priority Claims (3)
EP 11164991 · May 5, 2011 · regional
EP 11185064 · Oct 13, 2011 · regional
EP 12160007 · Mar 16, 2012 · regional
Continuity (4)
Provisional Application 61614135 · Mar 22, 2012
Provisional Application 61551598 · Oct 26, 2011
Provisional Application 61482830 · May 5, 2011
Related Publication 20120322739A1 · Dec 20, 2012